I-Cuban Academy of Sciences yenza imithi yokugoma yokwelapha umdlavuza wamaphaphu ongewona omncane- i-Vaxira ne-CIMAvax. Lolu hlobo lwakamuva lokugoma olukwazi ukwelapha umdlavuza wamaphaphu ongewona omncane (i-NSCLC) seluthole ukuqinisekiswa komtholampilo kwesigaba sesi-3 futhi lunomthelela omuhle kumdlavuza wamaphaphu weseli ongewona omncane. Manje isifake izicelo zomtholampilo Cuba futhi Peru. Imiphumela yalolu cwaningo oluthokozisayo yanika amandla owayenguMongameli waseMelika Barack Obama ukususa ukuvinjelwa kweminyaka engu-55 yokuhweba ngemuva kokuvakashela Cuba, and introduced the latest anti-cancer technology to the United States in 2015. The US Food and Drug Administration (FDA) has approved the United States to conduct a clinical trial of a lung cancer vaccine developed in Cuba, which can stimulate the lung cancer patient’s own immune system.
Kuyini i-CIMAvax?
CIMAvax-EGF is a umdlavuza wamaphaphu treatment that was developed in Cuba. It is a type of immunotherapy that harnesses the body’s immune system to fight lung cancer. In 2017, Roswell Park initiated a clinical trial involving CIMAvax. Trial is a Phase I/II study of CIMAvax-EGF in combination with the anti-PD1 checkpoint inhibitor nivolumab (Opdivo®) in patients previously treated for advanced umdlavuza wamaphaphu weselula ongewona omncane (NSCLC).
Isebenza kanjani iCIMAvax?
Ithuthukiswe abacwaningi eCentre for Molecular Immunology (CIM) eHavana, eCuba, i-CIMAvax-EGF ivimba uhlobo lwamaprotheni - i-epidermal growth factor (EGF) - amangqamuzana omdlavuza adinga ukukhula. Ayiwabulali amangqamuzana ngokuqondile, amangqamuzana anomdlavuza noma ngenye indlela, kodwa “iwalamba” ngokuvimbela i-EGF ukuthi inganamatheli ku-receptor yayo efanele (EGFR) kuseli. Lokhu kuxhumana kuyadingeka ukuze iseli likhule futhi ande. Ngaphandle kwawo, ingqamuzana lomdlavuza aliphindaphindeki, futhi liyafa. I-CIMAvax ivimba i-EGF ngokulawula impendulo yokuzivikela komzimba yesiguli.
“I-carrier protein” ku-CIMAvax icupha amasosha omzimba ukuthi akhiqize amasosha omzimba aphikisana ne-protein ye-EGF ukuze ayenze ingabi namandla. Lokhu kunciphisa ukujikeleza i-EGF kusuka egazini, kunciphisa amaseli womdlavuza walesi sikhiye esibalulekile ekukhuleni nasekusindeni.
More than 5,000 lung cancer patients have been treated with this unique immunotherapy, and several international studies have indicated prolonged isisu stabilization and improved overall survival and quality of life for patients receiving CIMAvax. CIMAvax is an approved treatment for lung cancer in Argentina, Bosnia and Herzegovina, Colombia, Cuba, Kazakhstan, Paraguay and Peru.
Kuyini uVaxira?
Vaxira® is a therapeutic vaccine for the treatment of non-small cell lung cancer (NSCLC). It is composed of Racotumomab and aluminum hydroxide adjuvant.
I-Racotumomab iyi-anti-idiotypic monoclonal antibody eyenza iziguli ziphendule amandla omzimba ngokulwa nama-gangliosides athile we-glycolylated (NeuGcGM3) akhona kumaseli wesimila. I-Vaxira® inyusa ukusinda kweziguli ze-NSCLC ezigabeni eziphindaphindayo noma ezisezingeni eliphakeme (IIIB / IV) uma kuqhathaniswa nokunakekelwa okuhle kakhulu. IVaxira® ibekezeleleke kahle futhi nephrofayili yayo yezokuphepha yamukelekile. Imicimbi emibi kakhulu ejwayelekile yenziwe yasendaweni (esizeni sokuphatha), imnene futhi yesikhashana.
Ngisho nalezo ziguli ezagonyelwa iVaxira® ngemuva kokuqhubekela phambili kwesifo sazo zikhombise ukuthuthuka ekusindeni jikelele.
Ukubunjwa: Isitsha ngasinye se-VAXIRA® siqukethe: mAb Racotumomab 1.00 mg, aluminium hydroxide [Al (OH) 3] 5.00 mg, tris (hydroxymethyl) aminomethane 12.14 mg, sodium chloride 3.40 mg, amanzi omjovo qs 1.0 ml. I-Vaxira® i-ejenti ye-immunotherapeutic eyakhiwe yi-anti-idiotypic monoclonal antibody Racotumomab ne-aluminium hydroxide (AH), i-adjuvant esetshenziswa kabanzi. I-AH ithuthukisa ukukhiqizwa kwama-antibodies, kepha akuyona i-immunogenic noma i-hapten. Isebenza njengedepho esizeni somjovo lapho i-antigen ikhishwa khona kancane futhi, ngasikhathi sinye, iheha ukwakheka kwama-granulomas aheha amaseli angenamandla amaningi njengamaseli e-plasma akhiqiza ama-antibody. I-AH ingakhuthaza ngqo ama-monocyte ukuthi akhiqize ama-cytokines ane-proinfigueatory angenza kusebenze ama-T cell, futhi futhi angavuselela nokuphendula kweseli B.
Ungayithenga kanjani i-CIMAvax neVaxira eNdiya?
CIMAvax and Vaxira at present are not available in India. These vaccines need to be ordered for personalized treatment. To order the medicine please WhatsApp patient details to + 91 96 1588 1588.
